Secondary prevention after coronary artery bypass graft surgery: a primer. (November 2016)

• Record Type: Journal Article
• Authors: Kulik, Alexander
• Is Part Of: Current opinion in cardiology. Volume 31:Number 6(2016:Nov.)
• Page Start: 635
• Page End: 643
• Publication Date: 2016-11
• Subjects: antiplatelet therapy -- coronary artery bypass graft surgery -- hypertension -- lipid-lowering therapy -- prevention; Cardiology -- Periodicals; Cardiology -- Periodicals; Heart Diseases -- Periodicals; Cardiology; Periodicals; 616.12
• DOI: 10.1097/HCO.0000000000000331
• Languages: English
• ISSNs: 0268-4705

Abstract

Abstract : Purpose of review: Despite the benefits of surgical coronary revascularization, patients continue to be at risk for ischemic events in the years that follow coronary artery bypass graft surgery (CABG), mandating the role for postoperative secondary preventive therapy. The purpose of this review was to present a summary on the subject of secondary prevention after CABG, including an overview of a recently published scientific statement, and highlight the newest studies in the field. Recent findings: Aspirin and statin therapy continue to be the mainstay of secondary prevention after CABG, although newer antiplatelet and lipid-lowering medicines are being actively studied for their potential benefits. Other important elements to secondary prevention after CABG include the aggressive management of hypertension, smoking cessation, and the initiation of cardiac rehabilitation. Summary: Secondary prevention is an essential component of postoperative care after CABG. Instituting preventive therapies after surgery optimizes graft patency and helps patients achieve the highest level of physical health and quality of life following CABG.